EDEN PRAIRIE, Minn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today that the company received registration from FDA Thailand to allow the sale of Aquadex Flex Flow® in Thailand. The product will be sold through the company’s current distributor in South-East Asia, Transmedic, adding to its earlier commercial launches in Hong Kong and Singapore.
"We continue to selectively pursue opportunities outside of the United States, and we look forward to working with our distribution partner, Transmedic, to further expand our reach in Asia,” commented John Erb, Chairman and Chief Executive Officer of CHF Solutions. “We continue to believe that the heart failure market remains largely untapped in Asia and anticipate that the Aquadex FlexFlow system will provide a clinically proven alternative therapy option when diuretics fail.”
The Aquadex FlexFlow is now available for patients in seven countries, including the United Kingdom, Germany, Italy, Spain, Hong Kong, Singapore and Thailand, in addition to the United States.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statements regarding the benefits from using the Aquadex FlexFlow system, the clinical benefits of the Aquadex FlexFlow system as compared to pharmacotherapy, our plans to commercialize the Aquadex Flex Flow system outside the United States, and our ability along with our distribution partner, Transmedic, to expand into other markets in Asia. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.
Source: CHF Solutions, Inc.